Table 1 Incidence and RR of all-grade and high-grade hypertension with targeted therapies
From: Risks and management of hypertension in cancer patients undergoing targeted therapy: a review
Type of cancer therapy | All-grade hypertension | High-grade hypertension | Reference | |||
|---|---|---|---|---|---|---|
Incidence (95% CI), % | RR (95% CI) | Incidence (95% CI), % | RR (95% CI) | |||
Monoclonal antibodies targeting VEGF | Bevacizumab | 23.6 (20.5–27.1) | 3.02 (2.24–4.07) | 7.9% (6.1–10.2%) | 5.28 (4.15–6.71) | [12] |
Ramucirumab | 16.4 (11.9–22.3) | 2.28 (1.61–3.24) | 9.8 (7.2–13.0) | 3.59 (2.32–5.53) | [13] | |
VEGF fusion molecules | Aflibercept | 42.4 (35.0–50.3) | 4.47 (3.84–5.22) | 17.4 (13.7–21.9) | 4.97 (3.95–6.27) | [14] |
Tyrosine kinase inhibitors | Sorafenib | 19.1 (15.8–22.4) | 3.07 (2.05–4.60) | 4.3 (3.0–5.5) | 3.31 (2.21–4.95) | [15] |
Sunitinib | 21.6 (18.7–24.8) | 3.44 (0.62–19.15) | 6.8 (5.3–8.8) | 22.72 (4.48–115.29) | [16] | |
Pazopanib | 35.9 (31.5–40.6) | 4.97 (3.38–7.30) | 6.5 (5.2–8.0) | 2.87 (1.16–7.12) | [17] | |
Axitinib | 40.1 (30.9–50.2) | 3.0 (1.29–6.97) | 13.1 (6.7–24) | 1.71 (1.21–2.43) | [18] | |
Regorafenib | 44.4 (30.8–59.0) | 3.76 (2.35–5.99) | 12.5 (5.2–27.1) | 8.39 (3.10–22.71) | [19] | |
Cabozantinib | 39.0 (33.9–44.3) | 5.48 (3.76–7.99) | 17.0 (12.4–20.4) | 5.09 (2.71–9.54) | Incidence: PI 2020a) RR: [20] | |
Vandetanib | 24.2 (18.1–30.2) | 5.1 (3.76–6.92) | 6.4 (3.3–9.5) | 8.06 (3.41–19.04) | [21] | |
Lenvatinib | 47.0 (35.4–58.9) | 3.47 (2.31–5.21) | 17.7 (10.2–28.9) | 11.54 (4.83–27.57) | Incidence: [22] RR: PI 2020 | |
Ponatinib | 45.5 (36.7–54.5) | NA | 22.7 (14.5–33.8) | NA | Incidence: PI 2020 | |
Nilotinib | 10.0 (7.0–14.2) | 4.01 (1.78–9.04) | 1.1 (0.3–3.3) | 3.01 (0.32–28.77) | Incidence: PI 2020 RR: compared with imatinib | |
Androgen inhibitors | Abiraterone | 21.9 (13.6–33.2) | 1.80 (1.47–2.19) | 10.2 (6.9–11.6) | 2.11 (1.66–2.68) | [5] |
Enzalutamide | 11.9 (8.8–16.0) | 2.82 (2.34–3.38) | 4.9 (3.5–6.8) | 2.27 (1.73–2.96) | [6] | |
Proteasome inhibitors | Bortezomib | 13 (10.0–17.3) | 1.78 (1.12–2.84) | 2.6 (1.4–5.0) | 4.46 (0.97–20.49) | PI 2020 |
Carfilzomib | 12.2 (9.8–14.9) | 2.71 (1.53–4.82) | 4.3 (2.6–6.4) | 3.0 (0.97–9.15) | Incidence: [7] RR: PI 2020 | |
PI3 kinase inhibitors | Copanlisib | 35.0 (28.3–42.6) | NA | 26 (21.3–31.0) | NA | Incidence: PI 2020 |
Bruton tyrosine kinase inhibitor | Ibrutinib | 19 (17.1–21.1) | 2.82 (1.52–5.23) | 8 (6.7–9.5) | RR: NA | Incidence: PI 2020. RR: [9] |